Literature DB >> 4751797

Possible evidence for interference with Venezuelan equine encephalitis virus vaccination of equines by pre-existing antibody to Eastern or Western Equine encephalitis virus, or both.

C H Calisher, D R Sasso, G E Sather.   

Abstract

During 1971, an epizootic of Venezuelan equine encephalitis (VEE) reached the United States. Laboratory tests were performed on a large number of sick, healthy, unvaccinated, and vaccinated horses. Neutralization (N) tests in cell cultures revealed that 153 of 193 (79.3%) equines outside the state of Texas and 175 of 204 (85.8%) within Texas (82.6% overall) had detectable N antibody to VEE virus a week or more after vaccination. Twenty-six of 40 (65%) non-Texas equines and 18 of 29 (62%) Texas equines which had no detectable antibody against VEE virus a week or more after vaccination had N antibody against Eastern equine encephalitis (EEE) or Western equine encephalitis (WEE) virus or both, whereas only 50 of 153 (32.7%) non-Texas equines and 82 of 175 (46.9%) Texas equines with demonstrable N antibody against VEE also had N antibody against EEE and/or WEE virus. In vaccinated equines, significant negative correlations were found between the occurrence of antibody to VEE and antibody to EEE and/or WEE virus. These findings support the hypothesis that pre-existing antibody to EEE and/or WEE virus may modify or interfere with infection by VEE virus. The epizoologic significance of this possibility is discussed briefly.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4751797      PMCID: PMC379832          DOI: 10.1128/am.26.4.485-488.1973

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  4 in total

1.  CLINICAL AND IMMUNOLOGIC INTERRELATIONSHIP AMONG VENEZUELAN, EASTERN, AND WESTERN EQUINE ENCEPHALOMYELITIS VIRUSES IN BURROS.

Authors:  R J BYRNE; G R FRENCH; F S YANCEY; W S GOCHENOUR; P K RUSSELL; H H RAMSBURG; O A BRAND; F G SCHEIDER; E L BUESCHER
Journal:  Am J Vet Res       Date:  1964-01       Impact factor: 1.156

2.  Viruses: the versatile parasites; the arthropod-borne group of animal viruses.

Authors:  J CASALS
Journal:  Trans N Y Acad Sci       Date:  1957-01

3.  An outbreak of Venezuelan equine encephalomeylitis in Central America. Evidence for exogenous source of a virulent virus subtype.

Authors:  P T Franck; K M Johnson
Journal:  Am J Epidemiol       Date:  1971-11       Impact factor: 4.897

4.  Antigenic variants of Venezuelan equine encephalitis virus: their geographic distribution and epidemiologic significance.

Authors:  N A Young; K M Johnson
Journal:  Am J Epidemiol       Date:  1969-03       Impact factor: 4.897

  4 in total
  11 in total

1.  Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Jesse H Erasmus; Robert L Seymour; Jason T Kaelber; Dal Y Kim; Grace Leal; Michael B Sherman; Ilya Frolov; Wah Chiu; Scott C Weaver; Farooq Nasar
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

3.  Venezuelan equine encephalitis vaccination survey in Arizona and New Mexico, 1972.

Authors:  R M Moore; J I Moulthrop; G E Sather; C L Holmes; R L Parker
Journal:  Public Health Rep       Date:  1977 Jul-Aug       Impact factor: 2.792

4.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

5.  Neutralizing antibody responses of humans and mice to vaccination with Venezuelan encephalitis (TC-83) virus.

Authors:  C A Fillis; C H Calisher
Journal:  J Clin Microbiol       Date:  1979-10       Impact factor: 5.948

Review 6.  Medically important arboviruses of the United States and Canada.

Authors:  C H Calisher
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

7.  Epidemiology of Emergent Madariaga Encephalitis in a Region with Endemic Venezuelan Equine Encephalitis: Initial Host Studies and Human Cross-Sectional Study in Darien, Panama.

Authors:  Amy Y Vittor; Blas Armien; Publio Gonzalez; Jean-Paul Carrera; Claudia Dominguez; Anayansi Valderrama; Greg E Glass; Davis Beltran; Julio Cisneros; Eryu Wang; Alex Castillo; Brechla Moreno; Scott C Weaver
Journal:  PLoS Negl Trop Dis       Date:  2016-04-21

8.  A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge.

Authors:  Lisa Henning; Kathrin Endt; Robin Steigerwald; Michael Anderson; Ariane Volkmann
Journal:  Front Immunol       Date:  2021-01-19       Impact factor: 7.561

Review 9.  Neurological Sequelae Resulting from Encephalitic Alphavirus Infection.

Authors:  Shannon E Ronca; Kelly T Dineley; Slobodan Paessler
Journal:  Front Microbiol       Date:  2016-06-20       Impact factor: 5.640

10.  Clinical and Serological Findings of Madariaga and Venezuelan Equine Encephalitis Viral Infections: A Follow-up Study 5 Years After an Outbreak in Panama.

Authors:  Jean-Paul Carrera; Yaneth Pittí; Juan C Molares-Martínez; Eric Casal; Reneé Pereyra-Elias; Lisseth Saenz; Isela Guerrero; Josefrancisco Galué; Fatima Rodriguez-Alvarez; Carmela Jackman; Juan Miguel Pascale; Blas Armien; Scott C Weaver; Christl A Donnelly; Amy Y Vittor
Journal:  Open Forum Infect Dis       Date:  2020-08-20       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.